Abbott Submits Dual Glucose-Ketone Sensor ‘Libre Duo’ to US FDA for DKA Prevention After European CE Mark

August 23, 2026

MedTech Dive USA

Overview

Abbott has filed an FDA application to launch its dual glucose-ketone sensor, Libre Duo, in the U.S. after receiving Europe’s CE mark. Approval is expected by year-end, with the device aiming to prevent diabetic ketoacidosis (DKA) through continuous ketone monitoring. Endocrinologists and diabetes groups are developing guidelines for interpreting and acting on this new data, and in Europe, the device offers 15-day use for adults and 10-day for children aged two and older. This technology promises to significantly enhance diabetes self-management and safety.

In Depth

Key Findings

Abbott has submitted an application to the U.S. Food and Drug Administration (FDA) for its innovative dual glucose-ketone sensor, ‘Libre Duo,’ aiming for market launch in the United States. Following its successful attainment of the CE Mark in Europe, U.S. approval is anticipated by the end of the year. The primary objective of this device is to contribute to the prevention of diabetic ketoacidosis (DKA), a potentially life-threatening complication, through continuous ketone monitoring.

Technical and Clinical Details

The Libre Duo is a small sensor worn on the patient’s skin, designed to measure both glucose and ketone levels in interstitial fluid in real-time. By integrating continuous ketone measurement with traditional continuous glucose monitoring (CGM) functionality, the device can issue early warnings when DKA risk increases. In Europe, it is designed for up to 15 days of use for adults and up to 10 days for children aged two and older. This dual monitoring capability will be a crucial tool, particularly for Type 1 diabetes patients and those on SGLT2 inhibitors, to detect early signs of euglycemic DKA (ketosidosis occurring even with normal blood glucose levels). Endocrinologists and diabetes organizations are currently actively developing new guidelines for interpreting the ketone data provided by Libre Duo and for appropriate clinical actions based on these insights.

Background and Industry Context

While blood glucose control has long been the primary focus in diabetes management, diabetic ketoacidosis (DKA) remains a severe complication, with euglycemic DKA being particularly challenging to diagnose due to normal blood glucose levels. Traditional ketone measurements, relying on urine strips or intermittent blood tests, have limitations in providing real-time trend data. Abbott’s Libre Duo aims to enhance DKA early detection and prevention by continuously monitoring both glucose and ketones, thereby significantly improving patient safety. This technology has the potential to establish a new standard in the CGM market and change the paradigm of diabetes management.

Strategic Significance and Outlook

The U.S. FDA approval of Abbott Libre Duo will mark a significant milestone in diabetes management, particularly in DKA prevention. Widespread adoption of this device will empower more individuals with diabetes to comprehensively understand their physiological state and intervene at appropriate times. This will lead to a reduction in DKA-related hospitalizations and severe complications, contributing to a lighter burden on the overall healthcare system. Furthermore, this dual monitoring technology is expected to be integrated with automated insulin delivery (AID) systems in the future, functioning as part of more advanced closed-loop systems. Libre Duo is poised to be a groundbreaking product that improves the quality of life for people with diabetes and significantly contributes to the advancement of precision and preventive medicine.

Source: https://www.medtechdive.com/news/5-questions-on-abbotts-glucose-ketone-sensors/828193/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.